FOR IMMEDIATE RELEASE
Boca Raton, FL — Aventusoft, the company behind HEMOTAG®, a breakthrough Heart Failure management system, is proud to announce the publication of a peer-reviewed study in Cardiovascular Science, showcasing its ability to deliver real-time, non-invasive intracardiac performance data that directly informs heart failure management.
“Non-Invasive Evaluation by the HEMOTAG™ Recording Device to Tailor Treatment of Acutely Decompensated Heart Failure.” Read the full study (DOI: 10.70322/cvs.2025.10007).
The prospective study, conducted at JFK Medical Center, Atlantis, FL in collaboration with cardiologists from the University of Miami and Cleveland Clinic Florida, evaluated HEMOTAG’s ability to monitor isovolumetric contraction time (IVCT) and highlights how HEMOTAG’s Full-Spectrum Heart Failure Management System enabled clinicians to detect subtle cardiac dysfunction. Guiding earlier, more effective intervention and accurate management during hospitalizations. Unlike conventional tools that rely on indirect markers, HEMOTAG measures chamber-specific function and hemodynamic patterns without surgery, implants, or wearables.
This publication reinforces HEMOTAG’s value as a transformative solution for clinicians seeking precise, actionable data to improve outcomes across all stages of heart failure care.
Results showed that IVCT measured daily by HEMOTAG decreased in parallel with NT-proBNP levels among hospitalized heart failure patients, suggesting it could serve as a reliable, non-invasive marker of treatment response. In contrast, the control group showed no significant change in IVCT or NT-proBNP. The study concluded that HEMOTAG could offer a non-invasive method to guide heart failure management. The technology demonstrated feasibility, safety, and clinical relevance, supporting its potential role in future remote management strategies.
“This study reinforces the clinical value of HEMOTAG in managing heart failure,” said Kaustubh Kale, Founder and CEO of Aventusoft. “By providing non-invasive, actionable data, HEMOTAG helps clinicians make more informed treatment decisions, improve patient outcomes, and potentially reduce costly hospital readmissions.”
The study supports HEMOTAG’s role in future remote heart failure management, especially for aging populations and those at high risk of decompensation.
About HEMOTAG
Founded in 2024 and headquartered in Boca Raton, FL, HEMOTAG® is advancing the global standard of care with its Full-Spectrum Heart Failure Management System. The company is focused on developing and commercializing the world’s first intracardiac chamber performance-based technologies—offering a new paradigm in early- to late-stage heart failure management, heart disease detection, and hemodynamics-based diagnostics. HEMOTAG’s platform combines cutting-edge quad-sensor device, mobile application, and cloud-based diagnostics to deliver clinical-grade insights across care settings—from hospitals and ambulatory centers to emergency departments and the home. These solutions are designed to fill critical gaps in cardiovascular care and enable earlier, more precise interventions.
Developed by Aventusoft, HEMOTAG is backed by non-dilutive funding from the National Institutes of Health (NIH), Department of Defense (DoD), National Science Foundation (NSF), and other federal agencies. Participation in the accelerator positions HEMOTAG for international growth and strengthens its mission to improve cardiac care for aging populations and communities globally.
Together, lets make heart failure manageable—not a life sentence. Learn more at: hemotag.com
Media Contact
David Flores
Director of Marketing
david@hemotag.com
+1 561-234-4040